MS Contin

Product NDC: 59011-264
11-digit product format: 590110264
Labeler code: 59011
Product ID: 59011-264_7132048d-6d8b-ad24-09ad-1d2d8c7e727e
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: morphine sulfate
Dosage form: TABLET, FILM COATED, EXTENDED RELEASE
Route: ORAL
Labeler: Purdue Pharma LP
Application: NDA019516
Marketing category: NDA
Marketing start: 1987-07-01
Marketing end: 0000-00-00
Substance: MORPHINE SULFATE
Active strength: 200 mg/1
Pharmacologic classes: Full Opioid Agonists [MoA],Opioid Agonist [EPC]
DEA schedule: CII
NDC exclude flag: E
Listing certified through: 2018-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	59011-264		D	Discontinued by firm		2026-08-17
excluded package	package	59011-264	59011-264-10	D	Discontinued by firm		2026-08-17

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 44 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	59011-264-10	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	59011-264-10	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	59011-264-10	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	59011-264-10	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	59011-264-10	D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	59011-264-10	D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	59011-264-10	D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	59011-264-10	D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	59011-264-10	D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	59011-264-10	D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	59011-264-10	D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	59011-264-10	D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	59011-264-10	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	59011-264-10	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	59011-264-10	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded product	product		I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	59011-264-10	I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded product	product		I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	59011-264-10	I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded product	product		I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	59011-264-10	I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded product	product		I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	59011-264-10	I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded product	product		I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	59011-264-10	I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded product	product		I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	59011-264-10	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded product	product		E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded package	package	59011-264-10	E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 42.

Orange Book products#

Current product rows page 1 of 1 · 5 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N019516-001	MS CONTIN	MORPHINE SULFATE	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29
N019516-002	MS CONTIN	MORPHINE SULFATE	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08
N019516-003	MS CONTIN	MORPHINE SULFATE	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12
N019516-004	MS CONTIN	MORPHINE SULFATE	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16
N019516-005	MS CONTIN	MORPHINE SULFATE	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 5 matching rows.

Application-product, TE code table
Application-product	TE code
N019516-001	AB
N019516-002	AB
N019516-003	AB
N019516-004	AB
N019516-005	AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 6 · 210 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	RLD / RS	Approval date	Source SHA-256
2026-08-18 06:07:40	2026-07	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-001	MS CONTIN	30MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1987-05-29	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-002	MS CONTIN	60MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1988-04-08	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-003	MS CONTIN	15MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1989-09-12	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-004	MS CONTIN	100MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD, RS	1990-01-16	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-005	MS CONTIN	200MG	TABLET, EXTENDED RELEASE / ORAL	AB	RLD	1993-11-08	`2680178bc6a6…`

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 6 · 210 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-08-18 06:07:40	2026-07	N019516-001	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-002	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-003	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-004	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N019516-005	AB	1	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N019516-001	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-002	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-003	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-004	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N019516-005	AB	1	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-001	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-002	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-003	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-004	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N019516-005	AB	1	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N019516-001	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-002	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-003	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-004	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N019516-005	AB	1	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-001	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-002	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-003	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-004	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N019516-005	AB	1	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-001	AB	1	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-002	AB	1	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-003	AB	1	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-004	AB	1	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N019516-005	AB	1	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-001	AB	1	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-002	AB	1	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-003	AB	1	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-004	AB	1	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N019516-005	AB	1	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-001	AB	1	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-002	AB	1	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-003	AB	1	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-004	AB	1	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N019516-005	AB	1	`2680178bc6a6…`

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
59011-264-10	2024-06-10	C162847	48780-1	9d75b9d0-add1-f424-e053-dadaa90a57ce	These highlights do not include all the information needed to use MS CONTIN ® safely and effectively. See full prescribing information for MS CONTIN. MS CONTIN ® (morphine sulfate extended-release tablets), for oral use CII Initial U.S. Approval: 1941
59011-264-10	2020-01-31	C162847	48780-1	9d75b9d0-add1-f424-e053-dadaa90a57ce	These highlights do not include all the information needed to use MS CONTIN ® safely and effectively. See full prescribing information for MS CONTIN. MS CONTIN ® (morphine sulfate extended-release tablets), for oral use CII Initial U.S. Approval: 1941

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
59011-264-10	EA - Each	59011-264	e4401831-07d4-4787-a9da-8282417ff1a2	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
morphine sulfate	ACTIVE INGREDIENT	X3P646A2J0	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
morphine	ACTIVE MOIETY	76I7G6D29C	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
cetostearyl alcohol	INACTIVE INGREDIENT	2DMT128M1S	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
D&C Red No. 30	INACTIVE INGREDIENT	2S42T2808B	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
D&C Red No. 7	INACTIVE INGREDIENT	ECW0LZ41X8	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
D&C Yellow No. 10	INACTIVE INGREDIENT	35SW5USQ3G	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
FD&C Blue No. 1	INACTIVE INGREDIENT	H3R47K3TBD	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
FD&C Blue No. 2	INACTIVE INGREDIENT	L06K8R7DQK	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
Ferrosoferric oxide	INACTIVE INGREDIENT	XM0M87F357	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
hydroxyethyl cellulose (140 MPA.S at 5%)	INACTIVE INGREDIENT	8136Y38GY5	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
hydroxypropyl cellulose	INACTIVE INGREDIENT	RFW2ET671P	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
hypromelloses	INACTIVE INGREDIENT	3NXW29V3WO	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
lactose	INACTIVE INGREDIENT	J2B2A4N98G	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
magnesium stearate	INACTIVE INGREDIENT	70097M6I30	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
polyethylene glycols	INACTIVE INGREDIENT	3WJQ0SDW1A	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
Polysorbate 80	INACTIVE INGREDIENT	6OZP39ZG8H	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
talc	INACTIVE INGREDIENT	7SEV7J4R1U	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9
titanium dioxide	INACTIVE INGREDIENT	15FIX9V2JP	MS CONTIN (MORPHINE SULFATE) TABLET, FILM COATED, EXTENDED RELEASE [PURDUE PHARMA LP]	9

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
MS Contin	MORPHINE SULFATE	Rhodes Pharmaceuticals LLC	c354b3bf-86c0-4bb8-8b1f-be2164942698	2026-05-18	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (NDA): 019516 application number: NDA019516

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
X3P646A2J0	MORPHINE SULFATE	6211-15-0	MORPHINE SULFATE

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
MS Contin	Purdue Pharma LP \| Purdue Pharmaceuticals L.P.	2017-03-23	HUMAN PRESCRIPTION DRUG LABEL	13